PCI Biotech: Financial calendar 2013
October 30, 2012 03:15 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} 5 February 2013 - Presentation of the fourth...
PCI Biotech: Finansiell kalender 2013
October 30, 2012 03:15 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} 5.februar 2013 - Presentasjon av rapport for 4.kvartal...
PCI Biotech: Third quarter 2012 report
October 30, 2012 03:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, Norway, 30 October 2012.Please find attached...
PCI Biotech: Resultatrapport for 3.kvartal 2012
October 30, 2012 03:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 30.oktober 2012Vedlagt er rapport for tredje...
PCI Biotech: Results from the first clinical study of Amphinex to be presented at the ESMO 2012 Congress in Vienna
September 24, 2012 09:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 24 September 2012 - PCI Biotech (PCIB) the...
PCI Biotech: Results from the first clinical study of Amphinex to be presented at the ESMO 2012 Congress in Vienna
September 24, 2012 09:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 24 September 2012 - PCI Biotech (PCIB) the...
PCI Biotech: Updated investor presentation
September 18, 2012 11:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Lysaker, 18 September 2012 - Attached is an updated...
PCI Biotech: Oppdatert investorpresentasjon
September 18, 2012 11:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Lysaker, 18.september 2012 - Vedlagt er en oppdatert...
PCI Biotech: Presentation of the PCI technology with clinical examples at the EACMFS 2012 Congress in Dubrovnik
September 10, 2012 02:57 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 10 September 2012 - PCI Biotech (PCIB) the...
PCI Biotech: Gallegangskreft (kolangiokarsinom) valgt som neste indikasjon for PCI Biotech. Klinisk studie forventes igangsatt senest 1H 2013
August 21, 2012 02:00 ET
|
PCI Biotech Holding ASA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Oslo, 21.august 2012 - PCI Biotech (PCIB) melder i...